Pathology consultation on monitoring direct thrombin inhibitors and overcoming their effects in bleeding patients

American Journal of Clinical Pathology

Volumn 140, Issue 5, 2013, Pages 610-622

  Winkler, Anne M ^a   Tormey, Christopher A ^b,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Direct thrombin inhibitors; Laboratory monitoring; Pathology consultation; Transfusion therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ARGATROBAN; DABIGATRAN ETEXILATE; DESULFATOHIRUDIN; ENOXAPARIN; HEPARIN; HIRULOG; LEPIRUDIN; WARFARIN;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULATION; BLEEDING; BRAIN ISCHEMIA; BRAIN TOMOGRAPHY; CASE REPORT; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; EMERGENCY WARD; FALLING; FEMALE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HIP PAIN; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MEDICAL HISTORY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PATHOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; SUBDURAL HEMATOMA; THROMBIN TIME; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM;

DIRECT THROMBIN INHIBITORS; LABORATORY MONITORING; PATHOLOGY CONSULTATION; TRANSFUSION THERAPY;

AGED; ALGORITHMS; ANIMALS; ANTITHROMBINS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG OVERDOSE; FEMALE; HEMORRHAGE; HEMOSTATIC TECHNIQUES; HUMANS; PATHOLOGY; REFERRAL AND CONSULTATION;

EID: 84886239113     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP9VJS6KUKNCHW     Document Type: Review

References (95)

1. Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011;72:581-592.
2. Tulinsky A. Molecular interactions of thrombin. Semin Thromb Hemost. 1996;22:117-124.
3. Nutescu EA, Shapiro NL, Chevalier A. New anticoagulant agents: direct thrombin inhibitors. Cardiol Clin. 2008;26:169-187.
4. Bates S, Weitz J. The mechanism of action of thrombin inhibitors. J Invasive Cardiol. 2000;12(suppl F):27F-32F.
5. Desirudin (Iprivask) [package insert]. Hunt Valley, MD: Canyon Pharmaceuticals, 2010.
6. Graetz TJ, Tellor BR, Smith JR, et al. Desirudin: a review of the pharmacology and clinical application for the prevention of deep vein thrombosis. Expert Rev Cardiovasc Ther. 2011;9:1101-1109.
7. Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am. 1997;79:326-333.
8. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 1997;337:1329-1335.
9. Frame JN, Rice L, Bartholomew JR, et al. Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis. Clin Ther. 2010;32:626-636.
10. Boyce SW, Bandyk DF, Bartholomew JR, et al. A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparininduced thrombocytopenia with or without thrombosis: PREVENT-HIT study. Am J Ther. 2011;18:14-22.
11. Serruys PW, Herrman J-PR, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1995;333:757-764.
12. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996;335:775-782.
13. Jeske WP, Fareed J, Hoppensteadt DA, et al. Pharmacology of argatroban. Expert Rev Hematol. 2010;3:527-539.
14. Argatroban [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2009.
15. Linkins L, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e495S-e530S.
16. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838-1843.
17. Lewis B, Wallis D, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849-1856.
18. Lewis BE, Matthai WH, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2002;57:177-184.
19. Rossig L, Genth-Zotz S, Rau M, et al. Argatroban for elective percutaneous coronary intervention: the ARG-E04 multicenter study. Int J Cardiol. 2011;148:214-219.
20. Vermeer F, Vahanian A, Fels PW, et al. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI study. J Thromb Thrombolysis. 2000;10:233-240.
21. LaMonte MP, Nash ML, Wang DZ, et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke. 2004;35:1677-1682.
22. Bivalirudin (Angiomax) [package insert]. Parsippany, NJ: The Medicines Co; 2010.
23. Van De Car DA, Rao SV, Ohman EM. Bivalirudin: a review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther. 2010;8:1673-1681.
24. Arsenault KA, Hirsh J, Whitlock RP, et al. Direct thrombin inhibitors in cardiovascular disease. Nat Rev Cardiol. 2012;9:402-414.
25. Dabigatran etexilate (Pradaxa) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2012.
26. Ageno W, Gallus AS, Wittkowsky A, et al. Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S-e88S.
27. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am J Cardiol. 2007;100:1419-1426.
28. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
29. Tran A, Cheng-Lai A. Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin. Cardiol Rev. 2011;19:154-161.
30. Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol. 2010;85:185-187.
31. Warkentin TE, Greinacher A, Craven S, et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost. 2005;94:958-964.
32. Arpino PA, Demirjian Z, Van Cott EM. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy. 2005;25:157-164.
33. Gosselin RC, King JH, Janatpour KA, et al. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother. 2004;38:1383-1388.
34. Ivandic B, Zorn M. Monitoring the anticoagulants argatroban and lepirudin: a comparison of laboratory methods. Clin Appl Thromb Hemost. 2011;17:549-555.
35. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105:371-378.
36. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Thromb Haemost. 2012;107:985-997.
37. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Crit Care Clin. 2011;27:805-823.
38. Rhea JM, Snyder ML, Winkler AM, et al. Development of a fast and simple liquid chromatography tandem mass spectrometry method for the quantitation of argatroban in patient plasma samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;893-894:168-172.
39. Hu ZY, Parker RB, Herring VL, et al. Conventional liquid chromatography/triple quadruple mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013;405:1695-1704.
40. Delavenne X, Moracchini J, Laporte S, et al. UPLC MS/MS assay for routine quantification of dabigatran: a direct thrombin inhibitor in human plasma. J Pharm Biomed Anal. 2012;58:152-156.
41. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23:138-143.
42. Harenberg J, Giese C, Marx S, et al. Determination of dabigatran in human plasma samples. Semin Thromb Hemost. 2011;38:16-22.
43. Curvers J, van de Kerkhof D, Stroobants AK, et al. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays. Am J Clin Pathol. 2012;138:551-558.
44. Calatzis A, Peetz D, Haas S, et al. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol. 2008;130:446-454.
45. Diehl KH, Römisch J, Hein B, et al. Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models. Haemostasis. 1995;25:182-192.
46. Zhou W, Schwarting S, Illanes S. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42:3594-3599.
47. Pragst I, Zeitler SH, Doerr B, et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost. 2012;10:1841-1848.
48. Lambourne MD, Eltringham-Smith LJ, Gataiance S, et al. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost. 2012;10:1830-1840.
49. Ibbotson SH, Grant PJ, Kerry R, et al. The influence of infusions of 1-desamino-8-d-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro. Thromb Haemost. 1991;65:64-66.
50. Butler KD, Dolan SL, Talbot MD, et al. Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP 39393) on bleeding in the rat. Blood Coagul Fibrinolysis. 1993;4:459-464.
51. Bove CM, Casey B, Marder VJ. DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb Haemost. 1996;75:471-475.
52. Wolzt M, Levi M, Sarich TC, et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost. 2004;91:1090-1096.
53. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-1579.
54. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108:217-224.
55. Young G, Yonekawa KE, Nakagawa PA, et al. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis. 2007;18:547-553.
56. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med. 2011;171:1285-1286.
57. Béné J, Saïd W, Rannou M, et al. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Ann Pharmacother. 2012;46:e14.
58. Truumees E, Gaudu T, Dieterichs C, et al. Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran). Spine (Phila Pa 1976). 2012; 37: E863-E865.
59. Garber ST, Sivakumar W, Schmidt RH. Neurosurgical complications of direct thrombin inhibitors-catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg. 2012;116:1093-1096.
60. Warkentin TE, Margetts P, Connolly SJ, et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 2012;119:2172-2174.
61. Harinstein LM, Morgan JW, Russo N. Treatment of dabigatran-associated bleeding: case report and review of the literature. J Pharm Pract. 2013;26:264-269.
62. Lillo-Le Louët A, Wolf M, Soufir L, et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost. 2012;108:583-585.
63. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012;46(4):e10.
64. Dumkow LE, Voss JR, Peters M, et al. Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. Am J Health Syst Pharm. 2012;69:1646-1650.
65. Cano EL, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother. 2012;10:160-163.
66. Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran in a life-threatening bleed occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med. 2013;41:e42-e46.
67. Casado Naranjo I, Portilla-Cuenca JC, Jiménez Caballero PE, et al. Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran. Cerebrovasc Dis. 2011;32:614-615.
68. Kernan L, Ito S, Shirazi F, et al. Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clin Toxicol (Phila). 2012;50:571-573.
69. Schattner A, Kozak N, Friedman J. Fatality in a patient treated with dabigatran. Am J Emerg Med. 2013;31:443.e1-e2.
70. Stratmann G, deSilva AM, Tseng EE, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg. 2004;98:1635-1639.
71. Nagle EL, Tsu LV, Dager WE. Bivalirudin for anticoagulation during hypothermic cardiopulmonary bypass and recombinant factor VIIa for iatrogenic coagulopathy. Ann Pharmacother. 2011;45:e47.
72. Mann MJ, Tseng E, Ratcliffe M, et al. Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia. J Heart Lung Transplant. 2005;24:222-225.
73. Apostolidou I, Sweeney MF, Missov E, et al. Acute left atrial thrombus after recombinant factor VIIa administration during left ventricular assist device implantation in a patient with heparin-induced thrombocytopenia. Anesth Analg. 2008;106:404-408.
74. Smith AI, Stroud R, Damiani P, et al. Use of argatroban for anticoagulation during cardiopulmonary bypass in a patient with heparin allergy. Eur J Cardiothorac Surg. 2008;34:1113-1114.
75. Edwards JT, Hamby JK, Worrall NK. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg. 2003;75:1622-1624.
76. Gasparovic H, Nathan NS, Fitzgerald D, et al. Severe argatroban-induced coagulopathy in a patient with a history of heparin-induced thrombocytopenia. Ann Thorac Surg. 2004;78:e89-91.
77. Genzen JR, Fareed J, Hoppensteadt D, et al. Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis. Transfusion. 2010;50:801-807.
78. Malherbe S, Tsui BC, Stobart K, et al. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology. 2004;100:443-445.
79. Yee AJ, Kuter DJ. Successful recovery after an overdose of argatroban. Ann Pharmacother. 2006;40:336-339.
80. Willey ML, de Denus S, Spinler SA. Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis. Pharmacotherapy. 2002;22:492-499.
81. Benz K, Nauck MA, Böhler J, et al. Hemofiltration of recombinant hirudin by different hemodialyzer membranes: implications for clinical use. Clin J Am Soc Nephrol. 2007;2:470-476.
82. Saravanan P, Rege K, Falter F. Use of continuous venovenous hemofiltration for reversal of anticoagulation with lepirudin post-cardiopulmonary bypass in a patient with heparininduced thrombocytopenia after heart transplantation. J Cardiothorac Vasc Anesth. 2007;21:269-272.
83. Stangier J, Rathgen K, Stähle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259-268.
84. Wanek MR, Horn ET, Elapavaluru S, et al. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother. 2012;46:e21.
85. Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013;61:487-489.
86. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-1127.
87. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87(suppl 1):S141-145.
88. Woo JS, Kapadia N, Phanco SE, et al. Positive outcome after intentional overdose of dabigatran. J Med Toxicol. 2012; 9:192-195.
89. US Food and Drug Administration. FDA news release: FDA approves Kcentra for the urgent reversal of anticoagulation in adults with major bleeding. April 29, 2013. Available at http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm350026.htm. Accessed May 9, 2013.
90. National Cancer Institute, National Institutes of Health. NCI common terminology criteria for adverse events (CTCAE), version 3. 2006. Available at http://ctep.cancer. gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf. Accessed May 9, 2013.
91. Ganetsky M, Babu KM, Salhanick SD, et al. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011;7:281-287.
92. Hedges SJ, Dehoney SB, Hooper JS, et al. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol. 2007;3:138-153.
93. Quaknine-Orlando B, Samama CM, Riou B, et al. Role of the hematocrit in a rabbit model of arterial thrombosis and bleeding. Anesthesiology. 1999;90:1454-1461.
94. Valeri CR, Khuri S, Ragno G. Nonsurgical bleeding diathesis in anemic thrombocytopenic patients: role of temperature, red blood cells, platelets, and plasma-clotting proteins. Transfusion. 2007;47:206S-248S.
95. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554-3562.